Advertisement
Advertisement
Trending on PharmExec
1
Pharmaceutical Executive Daily: Angelini Pharma Acquires Catalyst Pharmaceuticals in $4.1 Billion Agreement
2
Incyte Announces Week 24 Results from TRuE-AD4 Phase III Trial of Opzelura
3
Pharmaceutical Executive Daily: FDA Extends Review of Leqembi's sBLA
4
Pharma M&A Roundup: Bayer to Acquire Perfuse Therapeutics, Madrigal Enters Licensing Agreement for ARO-PNPLA3
5